Uncategorized Archives - Page 51 of 145

MondayMay 16, 2022 10:30 am

Aditxt Inc. (NASDAQ: ADTX) Is ‘One to Watch’

Aditxt is commercializing new innovations with focus on mapping and reprogramming the immune system Aditxt is actively adding distribution channel partners for AditxtScore(TM) throughout the U.S. and globally The company aims to expand reimbursement coverage for AditxtScore(TM) for COVID-19 from private insurance and public payers while developing and commercializing tests for other indications Aditxt intends to advance its ADi(TM) therapeutics pipeline into clinical trials in the coming months, with initial studies targeting psoriasis, type 1 diabetes, and skin allograft transplantation The company is led by a team of experts coming from a variety of different scientific fields and business backgrounds…

WednesdayMay 11, 2022 11:15 am

Silo Pharma Inc. (SILO) Spotlight: Ketamine

Ketamine shows promise in treating Alzheimer’s Disease, Parkinson’s Disease as well as depression, suicide ideation and more In 2021, Silo Pharma (OTCQB: SILO) entered into a joint venture with Zylö Therapeutics to “explore the clinical development of ketamine using ZTI’s Z-pod (transdermal) technology.” This innovative technology allows Silo, an early-stage biopharmaceutical company, to develop a ketamine delivery system for those suffering dysphagia, a difficulty or complete inability to swallow.(1) Silo Pharma is exploring the efficacy of ketamine in treating patients suffering from both Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”). Over 80% of PD patients(2) and 75% of AD patients(3)…

WednesdayMay 11, 2022 10:30 am

Investor Event Turns Spotlight on Novel Brain Cancer Drug Candidate Global Trial Under Way by CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)

CNS Pharmaceuticals is developing a proprietary drug candidate that has the potential to deliver a novel solution for unmet medical needs in treating an incurable brain cancer CNS’s drug candidate is called Berubicin, a powerful anthracycline that appears to be the first such chemotherapy agent able to successfully cross the blood-brain barrier Berubicin dosing has begun in a potentially pivotal global trial that is recruiting glioblastoma multiforme (“GBM”) brain cancer patients The FDA has granted CNS fast-track authorization in regard to Berubicin’s development, and European countries’ drug regulatory bodies are also granting authorization to advance the trial process there An…

FridayMay 06, 2022 9:00 am

Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Proprietary CYB003 Set to Move Forward in First-in-Human Phase 1/2a Clinical Trial

Cybin has selected Clinilabs Drug Development Corporation as CRO for its Phase 1/2a clinical trial evaluating CYB003 for treating major depressive disorder (“MDD”) MDD impacts more than 264 million people worldwide, is a leading cause of mental disability worldwide Preclinical studies show CYB003 may have significant advantages over classic psilocybin In a significant step forward in the study of alternative treatments for major depressive disorder, Cybin (NEO: CYBN) (NYSE American: CYBN) is moving forward in its phase 1/2a clinical trial of its proprietary deuterated psilocybin, CYB003 (https://ibn.fm/VTjoI). Based on previous research, CYB003 has the potential to effectively treat MDD with significant…

ThursdayApr 28, 2022 9:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Preclinical Data from CYB004 Study Showing Significant Advantages

Earlier studies show that CYB004 via inhalation may solve existing challenges and support a clinical path forward for this important therapeutic Cybin is currently developing CYB004 for the treatment of anxiety disorders The new chemical entity is covered by a patent issued earlier this year Cybin (NEO: CYBN) (NYSE American: CYBN) has released data from a pharmacokinetic study focused on evaluating CYB004, the company’s proprietary deuterated dimethyltryptamine (“DMT”) molecule (https://ibn.fm/nyCj8). The study analyzed delivery methods of CYB004, and showed initial data indicates significant advantages over Intravenous (“IV”) and Inhaled DMT. "In many studies, DMT has shown to be a promising and…

ThursdayApr 21, 2022 9:00 am

Silo Pharma Inc. (SILO) Advances with Pharmacokinetic Study – but What is Pharmacokinetics?

On March 31, 2022, Silo Pharma (OTCQB: SILO) announced an agreement with contract research organization Frontage Laboratories for an Investigational New Drug (“IND”)-enabling, “Pharmacokinetic Study.” Silo merges traditional therapeutics with psychedelic research to relieve patients suffering from PTSD, Alzheimer’s, Parkinson’s, and other rare neurological disorders. Frontage will study Silo’s Central Nervous System Peptide, SPU-16, “a potential new treatment for multiple sclerosis and other conditions,” and their Joint Homing Peptide, SPU-21, used for treating arthritogenic processes, which, according to Silo Pharma CEO Eric Weisblum, could, “enhance the therapeutic effect of current and future therapeutics while decreasing potential systemic toxicity….They may be…

MondayApr 18, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CYB004 Pipeline Program Receives Key Patent Approval from WIPO

World Intellectual Property Organization has published CYBN’s international patent application Publication of patent application demonstrates CYBN’s continued commitment to discovering, developing psychedelic-based treatment options Company continues to see strong protection for growing intellectual property portfolio of psychedelic-based compounds Cybin (NEO: CYBN) (NYSE American: CYBN) announced that the World Intellectual Property Organization (“WIPO”) has published an international patent application filed by Cybin. According to Cybin, the application, titled "Methods for Delivery of Psychedelic Medications by Inhalation and Systems for Performing the Methods," further strengthens Cybin’s long-term intellectual property (“IP”) position related to psychedelic-based programs. The application covers an array of inhalation delivery…

WednesdayApr 13, 2022 9:00 am

European Regulatory Approvals Help CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advance ‘Potentially Pivotal’ Study of Novel Brain Cancer Drug

Novel brain cancer drug developer CNS Pharmaceuticals is developing a proprietary pharmaceutical candidate called Berubicin for the treatment of glioblastoma multiforme (“GBM”) CNS has received Fast Track designation for Berubicin, which will allow the company more frequent communications with the FDA CNS has initiated a global potentially pivotal clinical trial to evaluate Berubicin in treating GBM and began dosing patients at sites scattered across several states last year, with numerous additional sites preparing to enroll patients in the coming months CNS is now reporting approval from regulatory authorities in Switzerland and France to proceed with recruiting patients there The study…

TuesdayApr 12, 2022 9:15 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Gaining Advantage on Processing Rare Cannabinoids with the Help of Subsidiary Bay Medica

There is an urgent need for large-scale biosynthetic processing that preserves the purity and consistency of cannabinoids Acquired by InMed in October 2021, Bay Medica is a private U.S. firm specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector InMed has two cannabinol formulations currently in development for ocular and dermatological diseases – INM-088 (ocular for glaucoma) and INM-755 (dermatological cream for epidermolysis bullosa) The global cannabis market increased exponentially after the pandemic hit, and is anticipated to continue its upward trend over the next few years. The market was valued at $20.47 billion…

TuesdayApr 12, 2022 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Provides Business Update, Marking 2021 Achievements

In 2021, Mydecine made significant progress in creating and commercializing new treatments for mental health and addiction disorders It also made a noteworthy shift in focus to reducing expenses and increasing efficiencies for continued clinical trials and the expansion of its IP portfolio For 2022, the company plans to build on the progress achieved in 2021 With new additions to its board, its conditional IRB approval, and the clinical research it has lined up for the new year, Mydecine is confident that it will meet its anticipated capital markets initiatives for 2022 Founded in 2020, Mydecine Innovations Group (NEO: MYCO)…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Aditxt Inc. (NASDAQ: ADTX) Is ‘One to Watch’

Silo Pharma Inc. (SILO) Spotlight: Ketamine

Investor Event Turns Spotlight on Novel Brain Cancer Drug Candidate Global Trial Under Way by CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)

Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Proprietary CYB003 Set to Move Forward in First-in-Human Phase 1/2a Clinical Trial

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Preclinical Data from CYB004 Study Showing Significant Advantages

Silo Pharma Inc. (SILO) Advances with Pharmacokinetic Study – but What is Pharmacokinetics?

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CYB004 Pipeline Program Receives Key Patent Approval from WIPO

European Regulatory Approvals Help CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advance ‘Potentially Pivotal’ Study of Novel Brain Cancer Drug

InMed Pharmaceuticals Inc. (NASDAQ: INM) Gaining Advantage on Processing Rare Cannabinoids with the Help of Subsidiary Bay Medica

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Provides Business Update, Marking 2021 Achievements

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search